News

Study findings Overall, overweight adults who lost enough weight to become healthy, and kept it off, had a lower risk of chronic disease. This was independent of the change in type 2 diabetes risk.
Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention. Now, a ...
Weight-loss drugs and bariatric surgery both have an impact on cancer risk. A new study breaks down the link and how GLP-1 RAs may help prevent the disease.
Another win for the jab. GLP-1 drugs like Ozempic and Wegovy have been linked to a host of benefits beyond diabetes management and weight loss, from reduced dementia risk to addiction treatment.
A new study involving nearly 1.7 million patients suggests that semaglutide — a drug that mimics a gut hormone to lower blood sugar and aid weight loss — could significantly cut dementia risk ...
Weight-loss injections, or GLP-1 receptor agonists, could nearly halve the risk of obesity-related cancers, a new study finds amid rising global obesity rates.
Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of dementia in people with type 2 diabetes (T2D).
GLP-1 weight loss and diabetes drugs like Ozempic and Wegovy may impact mental health, as studies show mixed results on mood changes, depression and anxiety.
Now, a study of 170,000 patient records suggests there’s a slightly lower risk of obesity-related cancers in U.S. adults with diabetes who took these popular medications compared to those who ...
Weight-loss drugs may lower cancer risk in people with diabetes, a study suggests After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% ...
Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Eli Lilly and Co.’s Zepbound could play a role in ...